Abstract: Trichilemmal carcinoma is a rare adnexal neoplasia with histologic features reminiscent of the outer root sheath of hair follicles. The clinical presentation of trichilemmal carcinoma is variable, as it may mimic basal cell carcinomas and squamous cell carcinomas, thus requiring histologic diagnosis. We report the case of a patient with aggressive trichilemmal carcinoma in the auricle.
INTRODUCTION
Trichilemmal carcinoma (TC)-also known as trichilemmocarcinoma-is a rare neoplasm that manifests as an asymptomatic exophytic or polypoid mass located in sun-exposed areas in older adults. TC may mimic basal or squamous cell carcinomas, keratoacanthomas and proliferating pilar tumors (PPT). 1,2 While described as locally destructive, surgical excision is reported to have positive clinical outcomes with low metastatic and recurrence rates. [1] [2] [3] [4] [5] Herein, we report the first Colombian case of a TC in an older adult, involving the retroauricular region.
CASE REPORT
An 84-year-old man presented to our clinic with a 5-year history of an ulcerated tumor arising from his left retroauricular region, with local destruction of the auricle (Figures 1 and 2 ). One year before, a biopsy performed at another institution reported it as a sclerodermiform basal cell carcinoma with squamous differentiation. A new biopsy was performed, identifying a multilobular 
DISCUSSION
Malignant hair follicle tumors account for 1% of adnexal carcinomas. 6 Prior to 2014, a total of 103 cases of TC had been reported; 60% of these cases occurred in men, 51% involved the face, and the average age of the patients was 72. 1, 4, 5, 8, 9 Nonetheless, safety margins of 1 cm have been used safely and cost-effectively. 4 However, over the past decade, Mohs micrographic surgery has been shown to have higher recurrence-free rates, becoming the gold standard treatment to preserve the surrounding healthy tissue. 1, 5 Additional therapeutic approaches include treatment with 5% imiquimod applied three times per week for eight weeks, for which no relapse has been observed at sixteen-month follow-up, and adjuvant radiotherapy for patients with high-risk disease. 1, 10 Since there are few articles reporting metastatic disease, magnetic resonance imaging and CT scan have been proposed as additional work-up studies for patients with TC. 6 There are currently no guidelines for treatment or follow-up of TC, but it is recommended that these tumors be treated as non-melanoma skin cancers. 
